1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

First Interchangeable Biosimilar Launched In US

Viatris And Biocon Introduce Semglee And Unbranded Insulin Glargine Biosimilars

 
• By Dave Wallace

Viatris and Biocon have introduced their interchangeable Semglee insulin glargine biosimilar in the US, along with an unbranded interchangeable version, marking the first ever launch of an interchangeable biosimilar. The non-interchangeable version is expected to be phased out rapidly.

Warning Sign Gamechanger
Interchangeability could be a gamechanger for Semglee • Source: Alamy

Biosimilars industry stakeholders will finally be able to see the effect of a US interchangeability designation on a product in the marketplace, after Viatris and Biocon launched their Semglee (insulin glargine-yfgn) and unbranded Insulin Glargine biosimilars in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products